FR2858628B1 - Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines - Google Patents

Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines

Info

Publication number
FR2858628B1
FR2858628B1 FR0309612A FR0309612A FR2858628B1 FR 2858628 B1 FR2858628 B1 FR 2858628B1 FR 0309612 A FR0309612 A FR 0309612A FR 0309612 A FR0309612 A FR 0309612A FR 2858628 B1 FR2858628 B1 FR 2858628B1
Authority
FR
France
Prior art keywords
nucleic acid
protein expression
rna interference
acid complexes
inhibiting protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0309612A
Other languages
English (en)
Other versions
FR2858628A1 (fr
Inventor
Patrick Erbacher
Abdemaji Adib
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polyplus Transfection SA
Original Assignee
Polyplus Transfection SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyplus Transfection SA filed Critical Polyplus Transfection SA
Priority to FR0309612A priority Critical patent/FR2858628B1/fr
Priority to PCT/FR2004/002086 priority patent/WO2005014837A1/fr
Publication of FR2858628A1 publication Critical patent/FR2858628A1/fr
Application granted granted Critical
Publication of FR2858628B1 publication Critical patent/FR2858628B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0309612A 2003-08-04 2003-08-04 Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines Expired - Lifetime FR2858628B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0309612A FR2858628B1 (fr) 2003-08-04 2003-08-04 Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines
PCT/FR2004/002086 WO2005014837A1 (fr) 2003-08-04 2004-08-04 Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhiber l'expression de proteines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0309612A FR2858628B1 (fr) 2003-08-04 2003-08-04 Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines

Publications (2)

Publication Number Publication Date
FR2858628A1 FR2858628A1 (fr) 2005-02-11
FR2858628B1 true FR2858628B1 (fr) 2008-01-04

Family

ID=34073010

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0309612A Expired - Lifetime FR2858628B1 (fr) 2003-08-04 2003-08-04 Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines

Country Status (2)

Country Link
FR (1) FR2858628B1 (fr)
WO (1) WO2005014837A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE555202T1 (de) 2004-08-16 2012-05-15 Immune Disease Inst Inc Verfahren zur lieferung von rna-interferenz und verwendungen damit
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
WO2008040792A2 (fr) 2006-10-04 2008-04-10 Centre National De La Recherche Scientifique (Cnrs) COMPOSITIONS INCLUANT UN siARN ET DES DÉRIVÉS LIPIDIQUES D'AMINOGLYCOSIDE À NOYAU 2-DÉSOXYSTREPTAMINE 4,5-DISUBSTITUÉE ET LEURS UTILISATIONS
FR2941152B1 (fr) * 2009-01-20 2013-10-18 Centre Nat Rech Scient Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques.
CA2819635A1 (fr) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Administration dirigee d'agents a une anatomie neuronale

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US6060456A (en) * 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
AU756301B2 (en) * 1997-08-20 2003-01-09 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
AU2001245987A1 (en) * 2000-03-24 2001-10-08 Biosphere Medical, Inc. Compositions and methods for gene therapy
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system

Also Published As

Publication number Publication date
FR2858628A1 (fr) 2005-02-11
WO2005014837A1 (fr) 2005-02-17

Similar Documents

Publication Publication Date Title
NO2017012I1 (no) HPV 45 L1 protein
DE60126828D1 (de) "pyrazolverbindungen, die sich als proteinkinaseinhibitoren eignen"
AU2001264811A1 (en) Methods for genetic analysis of dna to detect sequence variances
WO2005007814A3 (fr) Mappage genomique d'elements d'adn fonctionnels et de proteines cellulaires
DK1353941T3 (da) Modificerede zinkfingerbindingsproteiner
NO20020474L (no) Targeting av multimere kontrastmidler gjennom multilocus binding
DK1752470T3 (da) GAG-bindende proteiner
NO20015828D0 (no) Fremgangsmåter for fremstilling av 5'-nukleinsyre- proteinkonjugater
FR2796072B1 (fr) Peptides anti-microbiens de mollusques
FR2858628B1 (fr) Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines
DE602004015504D1 (de) Von injektionspräparaten
FR2775295B1 (fr) Fragment d'adn specifique de streptococcus agalactiae et molecules d'acides nucleiques apparentees
BR9710919A (pt) Proteina purificada sr-p70
DE60141221D1 (de) Verfahren zur genexpressionsanalyse
NO20041763L (no) Regulert nukleinsyreekspresjonssystem
FR2857003B1 (fr) Nouveau catalyseur pour le vaporeformage de l'ethanol
ATE278712T1 (de) Antikörper gegen plazentaprotein 13
DE60236511D1 (de) Biosynthetische gene zur herstellung von butenyl-spinosyn-haltigem insektizid
AU1351501A (en) Gene sequences identified by protein motif database searching
FR2862660B1 (fr) Systeme d'expression inductible de proteines recombinantes chez les cyanobacteries.
ATE368115T1 (de) Bakterielle insektizidproteine
EP1497305A4 (fr) Proteine 1 de liaison a l'adn sensible a l'insuline et methodes destinees a reguler des genes sensibles a l'insuline
EP1587928A4 (fr) Molecule d'acide nucleique humaine saa3, proteine, et procedes d'utilisation
AU2002361950A1 (en) Genes coding for dna replication proteins and for proteins related to pathogenesis
ITMI20040046A1 (it) Disposizione di scala d'alcova

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20